Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Big Pharma Split's revenue for the
six
months ended in Dec. 2025 was C$5.48 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was C$5.55 Mil.
Big Pharma Split's Revenue per Share for the
six
months ended in Dec. 2025 was C$4.21.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was C$4.27.
During the past 12 months, the average Revenue per Share Growth Rate of Big Pharma Split was 1093.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 22.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, Big Pharma Split's highest 3-Year average Revenue per Share Growth Rate was 25.50% per year. The lowest was -55.00% per year. And the median was -5.75% per year.
Big Pharma Split (TSX:PRM) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Big Pharma Split Revenue Related Terms
Big Pharma Split Revenue Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Big Pharma Split's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split Revenue vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's Revenue distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was C$5.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (TSX:PRM) has a Revenue of C$5.55 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's Revenue too high?
Big Pharma Split's current Revenue is C$5.55 Mil. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Revenue compare to BLK and BX?
Big Pharma Split's Revenue of C$5.55 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for an Asset Management company?
A good Revenue depends on the Asset Management industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Big Pharma Split and its competitors. Big Pharma Split's current Revenue is C$5.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Revenue of C$5.55 Mil. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current Revenue is C$5.55 Mil. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Revenue is C$5.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
Revenue: C$5.55 Mil
GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score
Get the complete analysis for TSX:PRM
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
